Clinical characteristics and prognostic value of pre‐retreatment plasma epstein‐barr virus DNA in locoregional recurrent nasopharyngeal carcinoma
Abstract Purpose To define the clinical characteristics and prognostic value of pre‐retreatment plasma Epstein‐Barr virus (EBV) DNA, we investigated EBV status in locoregional recurrent nasopharyngeal carcinoma (lrNPC) patients. Methods Between April 2008 and August 2016, the data of patients with n...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-08-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.2339 |
| _version_ | 1797847714989342720 |
|---|---|
| author | Ming‐Zhu Liu Shuo‐Gui Fang Wei Huang Han‐Yu Wang Yun‐Ming Tian Run‐Da Huang Zhuang Sun Chong Zhao Tai‐Xiang Lu Ying Huang Fei Han |
| author_facet | Ming‐Zhu Liu Shuo‐Gui Fang Wei Huang Han‐Yu Wang Yun‐Ming Tian Run‐Da Huang Zhuang Sun Chong Zhao Tai‐Xiang Lu Ying Huang Fei Han |
| author_sort | Ming‐Zhu Liu |
| collection | DOAJ |
| description | Abstract Purpose To define the clinical characteristics and prognostic value of pre‐retreatment plasma Epstein‐Barr virus (EBV) DNA, we investigated EBV status in locoregional recurrent nasopharyngeal carcinoma (lrNPC) patients. Methods Between April 2008 and August 2016, the data of patients with nonmetastatic lrNPC were retrospectively reviewed. The survival indexes of patients between different pre‐retreatment EBV status groups were compared. Results A total of 401 patients with nonmetastatic lrNPC were enrolled, and 197 (49.1%) patients had detectable pre‐retreatment plasma EBV DNA. Treatment included radiotherapy alone (n = 37 patients), surgery alone (n = 105), radiotherapy (n = 208), surgery combined with radiotherapy (n = 20), chemotherapy and targeted therapy (n = 31). Median follow‐up was 32 months. The 3‐year locoregional relapse‐free survival (LRRFS), distant metastasis‐free survival (DMFS), and overall survival (OS) rates for the entire cohort were 64.8%, 89.4%, and 58.8%, respectively. The estimated 3‐year LRRFS, DMFS, and OS rates for the pre EBV‐positive group vs the pre EBV‐negative group were 54.2% vs 75.0% (P < 0.001), 86.6% vs 91.9% (P = 0.05), 51.6% vs 65.9% (P = 0.01), respectively. Among patients in the clinical stage rI/II, there were 17 patients in the radiotherapy alone group and 49 patients in the surgery alone group. And there was no significant difference in overall survival between radiotherapy and surgery, even among the different pre‐EBV statuses (P > 0.05). In terms of long‐term toxic and side effects, the incidence of radioactive temporal lobe injury in the radiotherapy group was higher than that in the surgery group (35.3% vs 8.2%, P < 0.001), and no statistically significant difference was found in other long‐term toxic and side effects. Conclusions The positive rate of pre‐retreatment plasma EBV DNA in lrNPC is lower than primary NPC. The prognosis of EBV DNA negative group is better than positive group. For locally early‐stage lrNPC, regardless of EBV DNA status, radiotherapy and surgery are available options and both can achieve better long‐term survival. |
| first_indexed | 2024-04-09T18:15:51Z |
| format | Article |
| id | doaj.art-972f7213200247b58068f37933a19ccc |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-09T18:15:51Z |
| publishDate | 2019-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-972f7213200247b58068f37933a19ccc2023-04-13T04:36:19ZengWileyCancer Medicine2045-76342019-08-018104633464310.1002/cam4.2339Clinical characteristics and prognostic value of pre‐retreatment plasma epstein‐barr virus DNA in locoregional recurrent nasopharyngeal carcinomaMing‐Zhu Liu0Shuo‐Gui Fang1Wei Huang2Han‐Yu Wang3Yun‐Ming Tian4Run‐Da Huang5Zhuang Sun6Chong Zhao7Tai‐Xiang Lu8Ying Huang9Fei Han10Department of Radiation Oncology Sun Yat‐sen University Cancer Center Guangzhou Guangdong Province People's Republic of ChinaDepartment of Radiation Oncology Sun Yat‐sen University Cancer Center Guangzhou Guangdong Province People's Republic of ChinaDepartment of Radiation Oncology Sun Yat‐sen University Cancer Center Guangzhou Guangdong Province People's Republic of ChinaDepartment of Radiation Oncology Sun Yat‐sen University Cancer Center Guangzhou Guangdong Province People's Republic of ChinaDepartment of Radiation Oncology Hui Zhou Municipal Centre Hospital Huizhou Guangdong Province People's Republic of ChinaDepartment of Radiation Oncology Sun Yat‐sen University Cancer Center Guangzhou Guangdong Province People's Republic of ChinaDepartment of Radiation Oncology Sun Yat‐sen University Cancer Center Guangzhou Guangdong Province People's Republic of ChinaDepartment of Radiation Oncology Sun Yat‐sen University Cancer Center Guangzhou Guangdong Province People's Republic of ChinaDepartment of Radiation Oncology Sun Yat‐sen University Cancer Center Guangzhou Guangdong Province People's Republic of ChinaDepartment of Radiation Oncology Sun Yat‐sen University Cancer Center Guangzhou Guangdong Province People's Republic of ChinaDepartment of Radiation Oncology Sun Yat‐sen University Cancer Center Guangzhou Guangdong Province People's Republic of ChinaAbstract Purpose To define the clinical characteristics and prognostic value of pre‐retreatment plasma Epstein‐Barr virus (EBV) DNA, we investigated EBV status in locoregional recurrent nasopharyngeal carcinoma (lrNPC) patients. Methods Between April 2008 and August 2016, the data of patients with nonmetastatic lrNPC were retrospectively reviewed. The survival indexes of patients between different pre‐retreatment EBV status groups were compared. Results A total of 401 patients with nonmetastatic lrNPC were enrolled, and 197 (49.1%) patients had detectable pre‐retreatment plasma EBV DNA. Treatment included radiotherapy alone (n = 37 patients), surgery alone (n = 105), radiotherapy (n = 208), surgery combined with radiotherapy (n = 20), chemotherapy and targeted therapy (n = 31). Median follow‐up was 32 months. The 3‐year locoregional relapse‐free survival (LRRFS), distant metastasis‐free survival (DMFS), and overall survival (OS) rates for the entire cohort were 64.8%, 89.4%, and 58.8%, respectively. The estimated 3‐year LRRFS, DMFS, and OS rates for the pre EBV‐positive group vs the pre EBV‐negative group were 54.2% vs 75.0% (P < 0.001), 86.6% vs 91.9% (P = 0.05), 51.6% vs 65.9% (P = 0.01), respectively. Among patients in the clinical stage rI/II, there were 17 patients in the radiotherapy alone group and 49 patients in the surgery alone group. And there was no significant difference in overall survival between radiotherapy and surgery, even among the different pre‐EBV statuses (P > 0.05). In terms of long‐term toxic and side effects, the incidence of radioactive temporal lobe injury in the radiotherapy group was higher than that in the surgery group (35.3% vs 8.2%, P < 0.001), and no statistically significant difference was found in other long‐term toxic and side effects. Conclusions The positive rate of pre‐retreatment plasma EBV DNA in lrNPC is lower than primary NPC. The prognosis of EBV DNA negative group is better than positive group. For locally early‐stage lrNPC, regardless of EBV DNA status, radiotherapy and surgery are available options and both can achieve better long‐term survival.https://doi.org/10.1002/cam4.2339clinical characteristicsEpstein‐Barr Virus DNAprognosticrecurrent nasopharynx |
| spellingShingle | Ming‐Zhu Liu Shuo‐Gui Fang Wei Huang Han‐Yu Wang Yun‐Ming Tian Run‐Da Huang Zhuang Sun Chong Zhao Tai‐Xiang Lu Ying Huang Fei Han Clinical characteristics and prognostic value of pre‐retreatment plasma epstein‐barr virus DNA in locoregional recurrent nasopharyngeal carcinoma Cancer Medicine clinical characteristics Epstein‐Barr Virus DNA prognostic recurrent nasopharynx |
| title | Clinical characteristics and prognostic value of pre‐retreatment plasma epstein‐barr virus DNA in locoregional recurrent nasopharyngeal carcinoma |
| title_full | Clinical characteristics and prognostic value of pre‐retreatment plasma epstein‐barr virus DNA in locoregional recurrent nasopharyngeal carcinoma |
| title_fullStr | Clinical characteristics and prognostic value of pre‐retreatment plasma epstein‐barr virus DNA in locoregional recurrent nasopharyngeal carcinoma |
| title_full_unstemmed | Clinical characteristics and prognostic value of pre‐retreatment plasma epstein‐barr virus DNA in locoregional recurrent nasopharyngeal carcinoma |
| title_short | Clinical characteristics and prognostic value of pre‐retreatment plasma epstein‐barr virus DNA in locoregional recurrent nasopharyngeal carcinoma |
| title_sort | clinical characteristics and prognostic value of pre retreatment plasma epstein barr virus dna in locoregional recurrent nasopharyngeal carcinoma |
| topic | clinical characteristics Epstein‐Barr Virus DNA prognostic recurrent nasopharynx |
| url | https://doi.org/10.1002/cam4.2339 |
| work_keys_str_mv | AT mingzhuliu clinicalcharacteristicsandprognosticvalueofpreretreatmentplasmaepsteinbarrvirusdnainlocoregionalrecurrentnasopharyngealcarcinoma AT shuoguifang clinicalcharacteristicsandprognosticvalueofpreretreatmentplasmaepsteinbarrvirusdnainlocoregionalrecurrentnasopharyngealcarcinoma AT weihuang clinicalcharacteristicsandprognosticvalueofpreretreatmentplasmaepsteinbarrvirusdnainlocoregionalrecurrentnasopharyngealcarcinoma AT hanyuwang clinicalcharacteristicsandprognosticvalueofpreretreatmentplasmaepsteinbarrvirusdnainlocoregionalrecurrentnasopharyngealcarcinoma AT yunmingtian clinicalcharacteristicsandprognosticvalueofpreretreatmentplasmaepsteinbarrvirusdnainlocoregionalrecurrentnasopharyngealcarcinoma AT rundahuang clinicalcharacteristicsandprognosticvalueofpreretreatmentplasmaepsteinbarrvirusdnainlocoregionalrecurrentnasopharyngealcarcinoma AT zhuangsun clinicalcharacteristicsandprognosticvalueofpreretreatmentplasmaepsteinbarrvirusdnainlocoregionalrecurrentnasopharyngealcarcinoma AT chongzhao clinicalcharacteristicsandprognosticvalueofpreretreatmentplasmaepsteinbarrvirusdnainlocoregionalrecurrentnasopharyngealcarcinoma AT taixianglu clinicalcharacteristicsandprognosticvalueofpreretreatmentplasmaepsteinbarrvirusdnainlocoregionalrecurrentnasopharyngealcarcinoma AT yinghuang clinicalcharacteristicsandprognosticvalueofpreretreatmentplasmaepsteinbarrvirusdnainlocoregionalrecurrentnasopharyngealcarcinoma AT feihan clinicalcharacteristicsandprognosticvalueofpreretreatmentplasmaepsteinbarrvirusdnainlocoregionalrecurrentnasopharyngealcarcinoma |